Results 111 to 120 of about 4,391,067 (296)

Subtype diversity and emergence of drug resistance in HIV-1 in solapur district of Maharashtra, India

Iranian Journal of Microbiology, 2022
Background and Objectives: Even after four decades, HIV infection remains a global challenge and a leading cause of mortality in adults across the world.
Dilip D. Karad, Ravi Tandon, Ajay Arya, Kailash D. Sonawane, Anusaya S. Chavan, Arun S. Kharat   +5 more
doaj  

Prevalence of human immunodeficiency virus-1 drug-resistant mutations among adults on first- and second-line antiretroviral therapy in a resource-limited health facility in Busia County, Kenya

The Pan African Medical Journal, 2020
INTRODUCTION: In Kenya, about 1.5 million people are living with the Human Immunodeficiency Virus (HIV). Antiretroviral therapy aids in viral suppression. However, drug-resistance threaten the gains of the HIV infection control program.
Olipher Makwaga, Maureen Adhiambo, David Hughes Mulama, John Muoma, Ferdinard Adungo, Humphrey Wanjiku, Asiko Ongaya, Geoffrey Mutisya Maitha, Matilu Mwau   +8 more
doaj   +1 more source

Extensively drug resistant tuberculosis in South Africa [PDF]

, 2011
Includes abstract.Includes bibliographical references (leaves 161-168).There are few data for treatment-related outcomes in patients with XDR tuberculosis in settings with high HIV prevalence.
Shean, Karen Penelope
core   +1 more source

Advances in HIV-1 resistance detection technology

Guangxi Yike Daxue xuebao
HIV has ravaged the world for more than forty years, causing great pressure on global public health. Today, AIDS is still a medical challenge for global public health.
SHEN Kuiling, YAN huimin, LI Lin, LI Hanping   +3 more
doaj   +1 more source

TYPICAL FEATURES OF PRIMARY DRUG RESISTANCE AND VIABILITY OF MYCOBACTERIA IN TUBERCULOSIS PATIENTS WITH CONCURRENT HIV INFECTION

Туберкулез и болезни лёгких, 2017
Goal: to study the structure, profile of primary drug resistance and viability of mycobacteria in tuberculosis patients with concurrent HIV infection.Materials and methods.
N. M. Koretskaya, I. A. Bolshakova
doaj   +1 more source

Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria

Arthritis &Rheumatology, Accepted Article.
‐
Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle   +5 more
wiley   +1 more source

Self-Initiation of Antiretroviral Therapy in the Developing World: the Involvement of Private Pharmacies in an HIV Program. [PDF]

, 2012
Self-initiation to antiretroviral treatment (ART) exposes the patient to the risk of drug toxicity, poor adherence to treatment, and escalates the development of drug resistance.
Buma, Deus, Minzi, Omary Mashiku, Kagashe GA, Buma, D., Minzi OM, Buma D, Kagashe, G.A., Kagashe, Godeliver A, Minzi, O.M.   +8 more
core   +1 more source

New developments in HIV drug resistance [PDF]

Journal of Antimicrobial Chemotherapy, 2009
Several new antiretroviral drugs have recently been licensed for use in HIV-1-infected patients. These include drugs in two new classes: an integrase inhibitor (raltegravir) and a CCR5 co-receptor antagonist (maraviroc). In addition, two new protease inhibitors, atazanavir and darunavir, which have activity against viruses resistant to other protease ...
openaire   +2 more sources

Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Levofloxacin is a widely used antibiotic included in rifampicin‐resistant tuberculosis (RR‐TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR‐TB.
Sharon Sawe, Lufina Tsirizani, Buyisile Mkhize, Lubbe Wiesner, Gary Maartens, Francesca Conradie, Richard Court, Marian Loveday, Catriona Waitt, Paolo Denti   +9 more
wiley   +1 more source

Dihydropteroate synthase gene mutations in Pneumocystis and sulfa resistance [PDF]

, 2004
Pneumocystis pneumonia (PCP) remains a major cause of illness and death in HIV-infected persons. Sulfa drugs, trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone are mainstays of PCP treatment and prophylaxis.
Meja Rabodonirina, Chiara Atzori, Benfield, T, Helweg-Larsen, J, Rabodonirina, Meja, Robert Miller, Crothers, KA, Thomas Benfield, Huang, Laurence, Atzori, C, Rabodonirina, M, Laurence Huang, Kristina Crothers, Miller, R, Haung, L, Helweg-Larsen, Jannik, Jannik Helweg-Larsen, Miller, Robert, Crothers, Kristina, Benfield, Thomas, Atzori, Chiara   +20 more
core   +1 more source